Authors: Setnikar, I Schmid, K Rovati, LC Vens-Cappell, B Mazur, D Kozak, I

Citation: I. Setnikar et al., Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation, ARZNEI-FOR, 51(1), 2001, pp. 2-6

Authors: Wangemann, M Retzow, A Mazur, D Vens-Cappell, B

Citation: M. Wangemann et al., Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate, INT J CL PH, 38(8), 2000, pp. 395-401

Authors: Terhaag, B Hoffmann, A Barkworth, M Vens-Cappell, B

Citation: B. Terhaag et al., Bioavailability of a new effervescent tablet of diclofenac, INT J CL PH, 38(11), 2000, pp. 546-551

Authors: Retzow, A Althaus, M de Mey, C Mazur, D Vens-Cappell, B

Citation: A. Retzow et al., Study on the interaction of the dopamine agonist alpha-dihydroergocryptinewith the pharmacokinetics of digoxin, ARZNEI-FOR, 50(7), 2000, pp. 591-596

Authors: Wangemann, M Retzow, A Vens-Cappell, B

Citation: M. Wangemann et al., Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate, INT J CL PH, 37(2), 1999, pp. 100-108

Authors: Setnikar, I Rovati, LC Schmid, K Vens-Cappell, B Barkworth, MF

Citation: I. Setnikar et al., Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement, ARZNEI-FOR, 48(12), 1998, pp. 1172-1178